{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T23:06:04Z","timestamp":1777935964123,"version":"3.51.4"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T00:00:00Z","timestamp":1616976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005762","name":"National Taiwan University Hospital","doi-asserted-by":"publisher","award":["NTUH 107-S3747"],"award-info":[{"award-number":["NTUH 107-S3747"]}],"id":[{"id":"10.13039\/501100005762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST 109-2221-E-002 -163 -MY3"],"award-info":[{"award-number":["MOST 109-2221-E-002 -163 -MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Aging Neurosci."],"abstract":"<jats:p><jats:bold>Background and Objective:<\/jats:bold> Tau-specific positron emission topography (PET) imaging enables <jats:italic>in vivo<\/jats:italic> assessment of Alzheimer's disease (AD). We aimed to investigate its performance in combination with plasma tau levels in patients with non-AD tauopathy.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> A total of 47 participants were enrolled, including 10 healthy controls, 16 with tauopathy parkinsonism syndromes (9 with corticobasal syndrome [CBS], 7 with progressive supranuclear palsy [PSP]), 9 with frontotemporal dementia (FTD), 4 with AD, and 8 with Parkinson's disease (PD). All participants underwent clinical assessments, <jats:sup>18<\/jats:sup>F-T807 tau PET, brain MRI, and plasma tau assay.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> The global cortical standard uptake value ratio (SUVR) of <jats:sup>18<\/jats:sup>F-T807 PET was comparable between PD and control (<jats:italic>p<\/jats:italic> = 0.088). The cortical SUVR was significantly higher in AD group (<jats:italic>p<\/jats:italic> = 0.002) but was modestly increased in PSP group compared to the PD group (<jats:italic>p<\/jats:italic> = 0.044), especially in parietal and pallidal regions. Asymmetric <jats:sup>18<\/jats:sup>F-T807 uptake at the pallidum was noted in patients with CBS and FTD. Cortical tau tracer uptake was associated with increased plasma total tau level (<jats:italic>p<\/jats:italic> = 0.016), especially in frontal and parietal regions. Regional tracer uptake was correlated with cortical thinning in patients with CBS and PSP (CBS: <jats:italic>r<\/jats:italic> = \u22120.092, <jats:italic>p<\/jats:italic> = 0.025; PSP: <jats:italic>r<\/jats:italic> = \u22120.114, <jats:italic>p<\/jats:italic> = 0.015).<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> The <jats:sup>18<\/jats:sup>F-T807 tau tracer uptake was only modestly increased in patients with PSP. Although the cortical tau tracer uptake correlated with regional cortical atrophy and plasma tau levels, a four-repeated tau-specific tracer is needed for future classifying tauopathy parkinsonism syndromes.<\/jats:p>","DOI":"10.3389\/fnagi.2021.646440","type":"journal-article","created":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T04:56:01Z","timestamp":1616993761000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Integrated 18F-T807 Tau PET, Structural MRI, and Plasma Tau in Tauopathy Neurodegenerative Disorders"],"prefix":"10.3389","volume":"13","author":[{"given":"Cheng-Hsuan","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ta-Fu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Jang","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruoh-Fang","family":"Yen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Chieh","family":"Shih","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chin-Hsien","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1212\/WNL.0b013e31827f0fd1","article-title":"Criteria for the diagnosis of corticobasal degeneration","volume":"80","author":"Armstrong","year":"2013","journal-title":"Neurology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.2967\/jnumed.120.252411","article-title":"First tau PET tracer approved: toward accurate in vivo diagnosis of alzheimer disease","volume":"61","author":"Barthel","year":"2020","journal-title":"J. Nucl. Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e20200861","DOI":"10.1084\/jem.20200861","article-title":"Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer's disease","volume":"217","author":"Barth\u00e9lemy","year":"2020","journal-title":"J. Exp. Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s11910-019-0934-y","article-title":"New and old TSPO PET radioligands for imaging brain microglial activation in neurodegenerative disease","volume":"19","author":"Best","year":"2019","journal-title":"Curr. Neurol. Neurosci. Rep"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1212\/WNL.0000000000004364","article-title":"(18)F-AV-1451 binds to motor-related subcortical gray and white matter in corticobasal syndrome","volume":"89","author":"Cho","year":"","journal-title":"Neurology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/ana.24711","article-title":"In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum","volume":"80","author":"Cho","year":"2016","journal-title":"Annals Neurol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1002\/mds.26844","article-title":"Subcortical (18) F-AV-1451 binding patterns in progressive supranuclear palsy","volume":"32","author":"Cho","year":"","journal-title":"Mov. Disord"},{"key":"B8","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1177\/0271678X16683695","article-title":"Positron emission tomography imaging of tau pathology in progressive supranuclear palsy","volume":"37","author":"Coakeley","year":"2017","journal-title":"J. Cereb. Blood Flow Metab"},{"key":"B9","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.neuroimage.2006.01.021","article-title":"An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest","volume":"31","author":"Desikan","year":"2006","journal-title":"Neuroimage"},{"key":"B10","doi-asserted-by":"publisher","first-page":"Ii6","DOI":"10.1007\/BF03161076","article-title":"Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration","volume":"246","author":"Dickson","year":"1999","journal-title":"J. Neurol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1001\/jamaneurol.2020.0528","article-title":"Positron emission tomography imaging with [18F]flortaucipir and postmortem assessment of alzheimer disease neuropathologic changes","volume":"77","author":"Fleisher","year":"2020","journal-title":"JAMA Neurol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J. Psychiatr. Res"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","article-title":"Movement disorder society-sponsored revision of the unified parkinson's disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov. Disord"},{"key":"B14","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.neuroimage.2016.12.077","article-title":"PETPVE12: an SPM toolbox for partial volume effects correction in brain PET - application to amyloid imaging with AV45-PET","volume":"147","author":"Gonzalez-Escamilla","year":"2017","journal-title":"Neuroimage"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1212\/WNL.0b013e31821103e6","article-title":"Classification of primary progressive aphasia and its variants","volume":"76","author":"Gorno-Tempini","year":"2011","journal-title":"Neurology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s11910-018-0898-3","article-title":"The role of tau imaging in parkinsonian disorders","volume":"18","author":"Hammes","year":"2018","journal-title":"Curr. Neurol. Neurosci. Rep"},{"key":"B17","volume-title":"Statistical Methods for Meta-analysis.","author":"Hedges Lv","year":"1985"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1177\/0271678X18791430","article-title":"Regional times to equilibria and their impact on semi-quantification of [(18)F]AV-1451 uptake","volume":"39","author":"Heurling","year":"2019","journal-title":"J. Cereb. Blood Flow Metab"},{"key":"B19","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020)","author":"Higgins Jpt","year":"2020"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat. Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/mds.26987","article-title":"Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria","volume":"32","author":"H\u00f6glinger","year":"2017","journal-title":"Mov. Disord"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e0217384","DOI":"10.1371\/journal.pone.0217384","article-title":"An one-pot two-step automated synthesis of [18F]T807 injection, its biodistribution in mice and monkeys, and a preliminary study in humans","volume":"14","author":"Huang","year":"2019","journal-title":"PLoS ONE"},{"key":"B23","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","article-title":"Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases","volume":"55","author":"Hughes","year":"1992","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"key":"B24","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA research framework: toward a biological definition of Alzheimer's disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"key":"B25","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s00401-016-1618-1","article-title":"[18F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration","volume":"132","author":"Josephs","year":"2016","journal-title":"Acta Neuropathol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","article-title":"Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts","volume":"19","author":"Karikari","year":"2020","journal-title":"Lancet Neurol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.bj.2018.01.003","article-title":"Tau and neuroinflammation: what impact for Alzheimer's disease and tauopathies?","volume":"41","author":"Laurent","year":"2018","journal-title":"Biomed. J"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1038\/s41380-018-0342-8","article-title":"Tau PET imaging in neurodegenerative tauopathies-still a challenge","volume":"24","author":"Leuzy","year":"2019","journal-title":"Mol. Psychiatr"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e1104-11","DOI":"10.1212\/WNL.0000000000008088","article-title":"Blood NfL: a biomarker for disease severity and progression in Parkinson disease","volume":"93","author":"Lin","year":"2019","journal-title":"Neurology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3389\/fnagi.2018.00123","article-title":"Plasma biomarkers differentiate parkinson's disease from atypical parkinsonism syndromes","volume":"10","author":"Lin","year":"2018","journal-title":"Front Aging Neurosci"},{"key":"B31","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s40478-016-0315-6","article-title":"An autoradiographic evaluation of AV-1451 Tau PET in dementia","volume":"4","author":"Lowe","year":"2016","journal-title":"Acta Neuropathol. Commun"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14802\/jmd.17071","article-title":"Tau positron emission tomography imaging in degenerative parkinsonisms","volume":"11","author":"Lyoo","year":"2018","journal-title":"J. Mov. Disord"},{"key":"B33","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/ana.24844","article-title":"Pathological correlations of [F-18]-AV-1451 imaging in non-alzheimer tauopathies","volume":"81","author":"Marqui,\u00e9","year":"2017","journal-title":"Annals Neurol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1002\/ana.24517","article-title":"Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue","volume":"78","author":"Marqui,\u00e9","year":"2015","journal-title":"Ann. Neurol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.15252\/emmm.201707809","article-title":"18F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer's disease","volume":"9","author":"Mattsson","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"Mckhann","year":"2011","journal-title":"Alzheimers Dement"},{"key":"B37","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jalz.2018.02.013","article-title":"Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography","volume":"14","author":"Mielke","year":"2018","journal-title":"Alzheimers Dement"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/alzrt231","article-title":"Clinicopathologic assessment and imaging of tauopathies in neurodegenerative dementias","volume":"6","author":"Murray","year":"2014","journal-title":"Alzheimers Res. Ther"},{"key":"B39","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s00415-019-09566-9","article-title":"(18)F-AV1451 PET imaging and multimodal MRI changes in progressive supranuclear palsy","volume":"267","author":"Nicastro","year":"2020","journal-title":"J. Neurol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1007\/s00259-018-4104-2","article-title":"Disease-related patterns of in vivo pathology in Corticobasal syndrome","volume":"45","author":"Niccolini","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1093\/brain\/awu064","article-title":"Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET","volume":"137","author":"Okamura","year":"","journal-title":"Brain"},{"key":"B42","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1007\/s11910-014-0500-6","article-title":"Tau PET imaging in Alzheimer's disease","volume":"14","author":"Okamura","year":"","journal-title":"Curr. Neurol. Neurosci. Rep"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1093\/brain\/aww027","article-title":"Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease","volume":"139","author":"Ossenkoppele","year":"2016","journal-title":"Brain"},{"key":"B44","doi-asserted-by":"publisher","first-page":"10","DOI":"10.5483\/BMBRep.2020.53.1.309","article-title":"Peripheral inflammatory biomarkers in Alzheimer's disease: a brief review","volume":"53","author":"Park","year":"2020","journal-title":"BMB Rep"},{"key":"B45","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1093\/brain\/aww340","article-title":"18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy","volume":"140","author":"Passamonti","year":"2017","journal-title":"Brain"},{"key":"B46","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1126\/science.aag2590","article-title":"How neuroinflammation contributes to neurodegeneration","volume":"353","author":"Ransohoff","year":"2016","journal-title":"Science"},{"key":"B47","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1093\/brain\/awr179","article-title":"Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia","volume":"134","author":"Rascovsky","year":"2011","journal-title":"Brain"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1007\/s00259-019-04631-x","article-title":"Binding of [(18)F]AV1451 in post mortem brain slices of semantic variant primary progressive aphasia patients","volume":"47","author":"Schaeverbeke","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"B49","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.parkreldis.2019.07.001","article-title":"Multimodal neuroimaging relationships in progressive supranuclear palsy","volume":"66","author":"Sintini","year":"2019","journal-title":"Parkinsonism Related Disord."},{"key":"B50","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1002\/mds.26813","article-title":"Increased basal ganglia binding of (18) F-AV-1451 in patients with progressive supranuclear palsy","volume":"32","author":"Smith","year":"","journal-title":"Mov. Disord"},{"key":"B51","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1212\/WNL.0000000000004264","article-title":"In vivo retention of (18)F-AV-1451 in corticobasal syndrome","volume":"89","author":"Smith","year":"","journal-title":"Neurology"},{"key":"B52","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","article-title":"Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration","volume":"26","author":"Thijssen","year":"2020","journal-title":"Nat. Med"},{"key":"B53","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13195-019-0470-7","article-title":"(18)F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes","volume":"11","author":"Tsai","year":"2019","journal-title":"Alzheimers Res. Ther"},{"key":"B54","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/nrn.2015.1","article-title":"Tau in physiology and pathology","volume":"17","author":"Wang","year":"2015","journal-title":"Nat. Rev. Neurosci."},{"key":"B55","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11910-019-0962-7","article-title":"Tau imaging in neurodegenerative diseases using positron emission tomography","volume":"19","author":"Wang","year":"2019","journal-title":"Curr. Neurol. Neurosci. Rep"},{"key":"B56","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1212\/WNL.0000000000004667","article-title":"Serum neurofilament light in familial Alzheimer disease: a marker of early neurodegeneration","volume":"89","author":"Weston","year":"2017","journal-title":"Neurology"},{"key":"B57","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1002\/mdc3.12584","article-title":"Tau imaging in parkinsonism: what have we learned so far?","volume":"5","author":"Whitwell","year":"2018","journal-title":"Mov. Disord. Clin. Pract"},{"key":"B58","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/mds.26834","article-title":"[(18) F]AV-1451 tau positron emission tomography in progressive supranuclear palsy","volume":"32","author":"Whitwell","year":"2017","journal-title":"Mov. Disord"},{"key":"B59","doi-asserted-by":"publisher","first-page":"484","DOI":"10.2967\/jnumed.115.170910","article-title":"Pharmacokinetic evaluation of the Tau PET Radiotracer 18F-T807 (18F-AV-1451) in human subjects","volume":"58","author":"Wooten","year":"2017","journal-title":"J. Nucl. Med"}],"container-title":["Frontiers in Aging Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2021.646440\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T04:56:08Z","timestamp":1616993768000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2021.646440\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,29]]},"references-count":59,"alternative-id":["10.3389\/fnagi.2021.646440"],"URL":"https:\/\/doi.org\/10.3389\/fnagi.2021.646440","relation":{},"ISSN":["1663-4365"],"issn-type":[{"value":"1663-4365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,29]]},"article-number":"646440"}}